2023 is regarded by the industry as the first year for domestic innovative drugs to "go overseas" This year, domestic pharmaceutical companies have continued to increase their overseas projects. In the overseas market, opportunities and risks coexist.
In 2023, some people will be happy and some will be sad? This can be seen from the performance results announced by major companies. Some companies have narrowed their losses, and have taken steps to "burn money" in research and development. But the "going global" of innovative drugs also faces uncertainties.